Elevated concentrations of proinflammatory mediators, including interleukin 6 (IL-6), IL-8, IL-10 in CF tumor tissue prompted the use of tocilizumab and bevacizumab, achieving a decrease in cystic disease after initiation of combination therapy (39). Here, IL10 is linked to cystic fibrosis.